In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just<a class="excerpt-read-more" href=" More ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...